XERF arrives in the UK: promising early data, £4,500 price tag

A prospective multicentre study found aesthetic improvement in approximately 92% of 39 patients at 90 days after two XERF sessions. Its UK launch is set for September 2026, and one session can cost up to £4,500.

XERF—short for eXperience Exponential RF—is a dual-frequency radiofrequency device developed in South Korea in 2024 for clinical skin tightening and collagen stimulation without surgery or injections. It received FDA approval in 2025, followed by a gradual rollout in the United States and Canada.

The treatment became a favourite among A-listers and the beauty circle. Kim Kardashian has praised it, and Priyanka Chopra-Jonas has posted about it.

What does this change for patients?

Technology and candidate selection

Dr Nyla Raja, founder and medical director of Dr Nyla Medispa, calls XERF one of the most exciting developments in nonsurgical skin tightening. The device combines two radio frequencies to deliver controlled heat at different depths. Integrated cooling protects the surface while thermal energy reaches deeper tissue.

The heat contracts existing collagen fibres and stimulates collagen production and remodelling over subsequent weeks and months. Raja says the aim is better structural support, elasticity and definition, not a change to a patient’s underlying facial features.

The likely candidate has early loss of firmness, mild softness around the jawline, early jowling or reduced elasticity in the cheeks and lower face. Raja often sees these changes emerge from the late 30s onwards, although biological age matters more than the number on a birthday.

She prefers treating early laxity because nonsurgical options have natural limits once skin loses substantial structural support. Patients who want visible improvement but are not ready for surgery, or do not want an obvious procedure, may find XERF appealing.

Expected course and practical delivery

Raja said: “XERF isn’t a facelift, and I would never promise patients a dramatic transformation from a single treatment.” Some patients notice initial tightening, but more meaningful change develops gradually as collagen remodels over weeks and months. Results can be subtle and progressive rather than obvious overnight.

One session may suffice for mild laxity, while others may benefit from a course. Raja recommends reassessment after approximately three months. Maintenance could then be considered, perhaps annually, depending on skin and ageing, although the ideal long-term schedule has not been firmly established. She avoids unnecessary retreatment and bases maintenance on the response.

Device sessions generally take about 30–45 minutes depending on the area; XERF can treat the face and body. Raja describes a typical appointment as 45–60 minutes. Patients generally report a warming sensation and relatively low pain. Cooling improves comfort, and many need no anaesthetic cream.

Moments of stronger heat can occur, so practitioners should adjust settings to patient comfort and the clinical endpoint. Downtime is usually minimal. Temporary redness, warmth or mild swelling can occur, but most people return to usual activities, including exercise, straight away. Raja cautions that no energy-based treatment is risk-free, so experienced practitioners matter.

After treatment, Raja recommends a gentle cleanser, moisturiser and broad-spectrum SPF 50. Patients should avoid strong exfoliating acids, retinoids and excessive heat for the first day or two if the skin feels sensitive.

Facial fat and treatment selection

Facial fat loss remains a valid concern. Raja notes that facial fat supports youthful contours and should not be compromised; she considers damaging those fat compartments one of the great errors of aesthetic medicine.

XERF lets practitioners adjust depth and intensity according to anatomy, but she does not claim fat loss is impossible: excessive heating of deeper tissues can potentially affect fat. Long-term XERF-specific evidence on that risk remains under development.

Raja does not expect XERF to displace every tightening technology. Radiofrequency and ultrasound devices work at different depths with different forms of energy. Both can be effective, but she considers them noninterchangeable. She describes XERF as an evolution of established radiofrequency, with potentially greater flexibility in targeting tissue layers.

She sees it as one option in a portfolio selected by facial anatomy, desired correction and tolerance for downtime, not as a machine designed to do everything. That distinction matters because established treatments and XERF can address laxity through different mechanisms.

The early clinical evidence

Raja characterizes the evidence as encouraging for skin laxity, facial definition and patient satisfaction. The available studies nevertheless remain small.

• Prospective multicentre study: 39 patients reported aesthetic improvement in approximately 92% of participants at 90 days after two treatment sessions.
• Separate study: 16 women had improvements in facial skin quality, including wrinkles, texture and firmness, after one treatment. Investigators found no evidence of facial fat atrophy during three months of follow-up.

These datasets remain small. Larger independently conducted trials, longer follow-up and direct comparisons with established treatments are needed to establish safety, durability and comparative benefit. The short absence of detectable fat atrophy in 16 women offers reassurance over three months, not a definitive long-term answer.

Raja considers the underlying science of radiofrequency-induced collagen remodelling well established, but she separates that from device-specific evidence. She said: “The most exciting technology is ultimately the one that consistently delivers safe, reproducible results for our patients.”

Why Korea matters

Korean beauty culture has traditionally emphasized smooth, luminous, firm skin without an obviously treated appearance. Raja links demand for XERF-like devices to a wider shift from adding facial volume toward improving tissue quality, collagen, elasticity and structural support.

Facial ageing is more complex than volume loss: different layers age at different rates, and the field has long leaned heavily on injectables. The newer Korean devices reflect more refined energy delivery, depth and patient comfort, but she rejects automatic superiority over European or American products. Important innovations come from manufacturers worldwide, even as Korea accelerates the sector.

Her preferred endpoint is simple: the patient should look well, naturally youthful and entirely themselves, not obviously altered. The immediate question for UK practices is whether independent, longer-term data can define XERF’s safety, durability and place before patients commit to a premium price tag. The answer will determine whether the Korean device becomes routine care or remains a premium niche.